Faculty Opinions recommendation of Symptom dimensions are associated with progressive brain volume changes in schizophrenia.

Objectives Alzheimer’s disease (AD), impaired fasting glucose (IFG), and Type 2 diabetes mellitus (T2DM) were reported associated with smaller brain volumes. Nevertheless, the association of hyperglycemia with brain volume changes in AD patients remains unclear. To investigate this issue, structural magnetic resonance imaging was used to compare brain volumes among AD patients with different fasting glucose levels. Methods Eighty-five AD patients were divided into three groups based on their fasting glucose level as suggested by the American Diabetes Association: normal fasting glucose group (AD_NFG, n = 45), AD_IFG group (n = 15), and AD_T2DM group (n = 25). Sagittal 3D T1-weighted images were obtained to calculate the brain volume. Brain parenchyma and 33 brain structures were automatically segmented. Each regional volume was analyzed among groups. For regions with statistical significance, partial correlation analysis was used to evaluate their relationships with fasting glucose level, corrected for Mini-Mental State Examination score, age, education level, cholesterol, triglyceride, and blood pressure. Results Compared with the AD_IFG and AD_NFG groups, the volume of pons in AD_T2DM group was significantly smaller. Fasting glucose was negatively correlated with pontine volume. Conclusions T2DM may exacerbate pontine atrophy in AD patients, and fasting glucose level is associated with pontine volume.

Download Full-text

Abstract T P59: Brain Atrophy Rates Not Affected By Stroke Thrombolysis

Stroke ◽

10.1161/str.46.suppl_1.tp59 ◽

2015 ◽

Vol 46 (suppl_1) ◽

Author(s):

Amy Brodtmann

Keyword(s):

Brain Atrophy ◽

Brain Volume ◽

Intravenous Thrombolysis ◽

Stroke Patients ◽

Volume Changes ◽

Significant Difference ◽

Siemens Trio ◽

Healthy Control ◽

Stroke Thrombolysis ◽

Global Brain

Introduction: Despite clear outcome benefits, some physicians remain concerned about theoretical deleterious effects of intravenous thrombolysis. In the CANVAS study (Cognition and Neocortical Volume After Stroke) we have reported brain volume changes in patients following stroke. We sought here to compare brain atrophy rates of 3 groups of patients presenting with MCA stroke, versus a group of healthy control participants. Hypothesis: We hypothesized that IV thrombolysis would not affect brain atrophy rates following stroke. Methods: Three groups of patients with acute ischemic MCA stroke were included, 2 of whom received thrombolysis: 10 patients were imaged at 2 hours and at 3 months (Copenhagen cohort) and 9 patients imaged within 30 days of symptom onset and at 3 months (Melbourne CANVAS cohort). We compared regional and global brain volume and atrophy rates with 10 patients who did not receive thrombolysis and a group of 10 healthy control participants were also imaged at these timepoints. 3D MPRAGE images were acquired on a Siemens Trio 3T MRI scanner. Images were processed using Freesurfer V 5.1 with default settings. We compared baseline and 3 month average regional cortical thickness. Ipsilesional and contralesional results were analyzed separately. Paired sample t-tests were used to assess significant change. Results: There was no significant difference in brain volume between the 2 timepoints in our control participants. Ipsilesional white matter (WM) and gray matter (GM) volume declined over the 3 month period in all 3 stroke groups. There was no significant difference in brain atrophy rates between stroke patients who received IV thrombolysis and those who didn’t. Conclusions: In this pilot study, we found that thrombolysis did not affect brain atrophy rates in the stroke patients studied.

Download Full-text